LyondellBasell Industries N.V. Free cash flow decreased by 150.9% to -$538.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 49.3%, from -$1.06B to -$538.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -49.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.47B | $1.63B | $2.41B | $1.06B | $1.07B | $975.00M | $1.13B | $130.00M | $989.00M | $1.27B | $1.02B | -$597.00M | $864.00M | $302.00M | $1.41B | -$1.06B | -$188.00M | $577.00M | $1.06B | -$538.00M |
| QoQ Change | — | +10.7% | +47.6% | -56.1% | +1.0% | -8.6% | +16.0% | -88.5% | +660.8% | +28.6% | -19.8% | -158.5% | +244.7% | -65.0% | +367.2% | -175.3% | +82.3% | +406.9% | +83.2% | -150.9% |
| YoY Change | — | — | — | — | -27.5% | -40.1% | -53.0% | -87.7% | -7.3% | +30.5% | -9.8% | -559.2% | -12.6% | -76.3% | +38.3% | -77.9% | -121.8% | +91.1% | -25.1% | +49.3% |